Introduction We estimated the age-specific duration of the preclinical, prodromal, and dementia
stages of Alzheimer's disease (AD) and the influence of sex, setting, apolipoprotein E (…

White matter hyperintensities (WMHs) are frequently seen on brain magnetic resonance
imaging scans of older people. Usually interpreted clinically as a surrogate for cerebral small …

Background Increased total tau (t-tau) in cerebrospinal fluid (CSF) is a key characteristic of
Alzheimer’s disease (AD) and is considered to result from neurodegeneration. T-tau levels, …

Introduction Plasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a “Holy
Grail” of AD research and intensively sought; however, there are no well-established …

Background Biomarker-based risk predictions of dementia in people with mild cognitive
impairment are highly relevant for care planning and to select patients for treatment when …

Alzheimer’s disease is biologically heterogeneous, and detailed understanding of the processes
involved in patients is critical for development of treatments. CSF contains hundreds of …

… Author links open overlay panel Isabelle Bos a , Stephanie Vos a , Frans Verhey a , Philip
Scheltens b , Charlotte Teunissen c , Sebastiaan Engelborghs d e f , Kristel Sleegers f g , …

Introduction Machine learning (ML) may harbor the potential to capture the metabolic
complexity in Alzheimer Disease (AD). Here we set out to test the performance of metabolites in …

Background There is an urgent need for novel, noninvasive biomarkers to diagnose Alzheimer’s
disease (AD) in the predementia stages and to predict the rate of decline. Therefore, we …

Background With the shift of research focus towards the pre-dementia stage of Alzheimer’s
disease (AD), there is an urgent need for reliable, non-invasive biomarkers to predict amyloid …